1. Academic Validation
  2. Small-Molecule Inhibitors of Haemophilus influenzae IgA1 Protease

Small-Molecule Inhibitors of Haemophilus influenzae IgA1 Protease

  • ACS Infect Dis. 2019 Jul 12;5(7):1129-1138. doi: 10.1021/acsinfecdis.9b00004.
Livia Shehaj 1 Santosh K Choudary 1 Kamlesh M Makwana 1 Mary C Gallo 2 3 Timothy F Murphy 2 3 4 Joshua A Kritzer 1
Affiliations

Affiliations

  • 1 Department of Chemistry , Tufts University , 62 Talbot Avenue , Medford , Massachusetts 02155 , United States.
  • 2 Department of Microbiology and Immunology , University at Buffalo, Jacobs School of Medicine and Biomedical Sciences , 3435 Main Street , Buffalo , New York 14203 , United States.
  • 3 Clinical and Translational Research Center , University at Buffalo, Jacobs School of Medicine and Biomedical Sciences , 875 Ellicott Street , Buffalo , New York 14203 , United States.
  • 4 Division of Infectious Disease, Department of Medicine , University at Buffalo, Jacobs School of Medicine and Biomedical Sciences , 875 Ellicott Street , Buffalo , New York 14203 , United States.
Abstract

Newly identified, nontypable Haemophilus influenzae (H. influenza) strains represent a serious threat to global health. Due to the increasing prevalence of Antibiotic resistance, virulence factors have emerged as potential therapeutic targets that would be less likely to promote resistance. IgA1 proteases are secreted virulence factors of many Gram-negative human pathogens. These enzymes play important roles in tissue invasion as well as evasion of the immune response, yet there has been limited work on pharmacological inhibitors. Here, we report the discovery of the first small molecule, nonpeptidic inhibitors of H. influenzae IgA1 proteases. We screened over 47 000 compounds in a biochemical assay using recombinant protease and identified a hit compound with micromolar potency. Preliminary structure-activity relationships produced additional inhibitors, two of which showed improved inhibition and selectivity for IgA protease over other serine proteases. We further showed dose-dependent inhibition against four different IgA1 protease variants collected from clinical isolates. These data support further development of IgA Protease Inhibitors as potential therapeutics for antibiotic-resistant H. influenza strains. The newly discovered inhibitors also represent valuable probes for exploring the roles of these proteases in Bacterial colonization, invasion, and Infection of mucosal tissues.

Keywords

FRET assay; IgA1 protease; antibacterial resistance; high-throughput screening; protease inhibitors.

Figures
Products